GlassScriptPhysician profile
Chloe G Smith
NPI 1932753316
$3,200.21
in general payments reported to CMS, 2019-2025
45 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.90 · 2022: $71.56 · 2023: $935 · 2024: $809 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $366.14 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $226.57 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $181.70 | 2023-2025 | |
| Seagen INC. | $148.81 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $144.34 | 2025 | Tecentriq, Polivy, Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.85 | 2023-2025 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $132.64 | 2024-2025 | Ninlaro, Fruzaqla, Iclusig |
| Astrazeneca Pharmaceuticals LP | $123.31 | 2023-2025 | Imfinzi, Enhertu |
| Deciphera Pharmaceuticals INC. | $122.82 | 2023-2024 | Qinlock |
| Stemline Therapeutics INC. | $110.45 | 2024-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $102.11 | 2023-2025 | Libtayo |
| Pharmaessentia USA Corporation | $99.17 | 2023-2024 | Besremi |
| Incyte Corporation | $95.57 | 2025 | Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $85.18 | 2023-2025 | Enhertu |
| Janssen Scientific Affairs, LLC | $79.34 | 2024 | Rybrevant |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $70.51 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $68.46 | 2023-2024 | Xarelto |
| Exelixis INC. | $67.37 | 2023-2025 | Cabometyx |
| Eisai INC. | $66.87 | 2022-2023 | |
| Emd Serono, INC. | $64.62 | 2025 | |
| Immunocore Limited | $62.36 | 2025 | Kimmtrak |
| Lilly USA, LLC | $58.01 | 2022-2023 | Jaypirca, Verzenio, Retevmo |
| Alexion Pharmaceuticals, INC. | $43.88 | 2023-2025 | Ultomiris, Soliris |
| Adc Therapeutics America, INC. | $39.86 | 2023-2025 | |
| Tersera Therapeutics LLC | $33.63 | 2022-2023 | Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $33.49 | 2023 | Imbruvica, Epkinly |
| Servier Pharmaceuticals LLC | $33.46 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.59 | 2023-2025 | |
| Astellas Pharma US INC | $30.33 | 2023-2024 | Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $29.81 | 2025 | |
| Axogen | $27.70 | 2021 | |
| Dendreon Pharmaceuticals LLC | $26.95 | 2024 | Provenge |
| Myriad Genetic Laboratories, INC. | $26.81 | 2024 | Bracanalysis Cdx |
| Genzyme Corporation | $26.19 | 2023 | |
| Karyopharm Therapeutics INC. | $25.02 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $23.69 | 2025 | |
| Verity Pharmaceuticals INC. | $22.51 | 2024 | Trelstar |
| Glaxosmithkline, LLC. | $22.02 | 2024 | Ojjaara |
| Puma Biotechnology, INC. | $19.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.98 | 2025 | Opdivo |
| Amgen INC. | $15.95 | 2023 | Nplate, Xgeva, Vectibix |
| Alnylam Pharmaceuticals INC. | $15.46 | 2025 | Givlaari |
| Aveo Pharmaceuticals, INC. | $14.30 | 2025 | |
| Allergan, INC. | $14.20 | 2021 | |
| Sumitomo Pharma America, INC. | $14.02 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.